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background:  Opening of the mitochondrial permeability transition pore (PTP) plays a key role in lethal myocardial reperfusion injury. 
Cyclophilin D (CypD) is a mitochondrial matrix protein that triggers PTP opening upon calcium accumulation at the time of reperfusion. The 
currently available cyclophilin inhibitor cyclosporin A (CsA) has some potential drawbacks including immunosuppression and several drug 
interactions. Our aim was to determine whether NVP019, a new non-immunosuppressive cyclophilin inhibitor with minimal off-target effects, 
might limit PTP opening, blunt lethal reperfusion injury and reduce infarct size.
methods and Results:  Anesthetized mice underwent 45 minutes of coronary artery occlusion followed by 24 hours of reperfusion. Area at 
risk (AAR) was assessed by blue dye injection and infarct size (IS) by triphenyltetrazolium chloride staining. Mice received either NVP019 
(10 mg/kg) or vehicle (saline), administered as an IV bolus 5 minutes prior to reperfusion (n=9-10/group). In additional experiments, 
mitochondria were isolated from the risk region at the end of reperfusion and PTP opening was assessed in vitro by measuring the calcium 
retention capacity (CRC)(n=5/group). Further, PTP was analyzed in mitochondria isolated from CypD-KO mice as well as human atrial and 
ventricular tissue samples. AAR was comparable among groups. NVP019 reduced IS from 48±7% in control to 36±8% of AAR (p<0.01), 
and increased CRC that averaged 935±114 vs 469±52 nmoles Ca2+/mg prot in control (p<0.0001). Importantly, NVP019 demonstrated 
similar potency in inhibiting PTP in both rodent and human heart mitochondria (IC50 4-6 nM), but did not further increase the CRC in 
mitochondria isolated from CypD-KO mice hearts.
conclusion:  NVP019 reduces myocardial infarct size likely by the inhibition of PTP opening in a CypD-dependent manner.
